Key facts, as of
As of September 29, 2026, Danaher Corporation (DHR) trades at $226.11, up 21.5% over the past year. Its 52-week range runs from $160.93 to $242.80; the price is 6.9% below that high. It sits 12.0% above its 200-day average of $201.80, the usual sign of a long-term uptrend. Its 30-day volatility is 24.3% annualized, which we rate medium risk. It has a trailing P/E of 40.2 and a dividend yield of 0.70%.
Cite: Portfolio Terminal, "Danaher Corporation (DHR) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/dhr
Where it trades today
trading 80% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- DHR trades at 40.2x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- DHR carries a beta of 0.81, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- DHR is in a bullish short-term regime and only 6.9% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- DHR is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in DHR.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for DHR come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for DHR. Last refresh: Sep 29, 2026, 10:32 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Danaher Corporation does
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design…
Employees
58,000
Industry
Diagnostics & Research
Headquarters
Washington, United States
What analysts expect
DHR carries a strong buy consensus from 23 analysts, with an average price target of $230.83 versus $226.11 today (+2.1%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DHR generated $25.11B in trailing revenue (5.5% year over year), with a 15.9% net margin, and $4.33B of free cash flow, against $23.51B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $24.57B | $14.52B | $4.69B | $3.61B | $5.07 | $5.26B |
| 2024 | $23.88B | $14.21B | $4.86B | $3.90B | $5.33 | $5.30B |
| 2023 | $23.89B | $14.03B | $5.20B | $4.76B | $6.44 | $5.78B |
| 2022 | $26.64B | $16.19B | $7.54B | $7.21B | $9.80 | $7.40B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
DHR beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, pressing toward $233.39 resistance.
uptrend- Price is 9.3% above its 50-day average and 12.0% above its 200-day.
- The 50-day crossed above the 200-day on 2026-09-14 (a “golden cross”).
- RSI at 69 is neither stretched nor washed out.
- The nearest ceiling is $233.39 (+3.2%), the nearest floor $221.64 (-2.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is DHR a good buy right now?
Danaher Corporation trades at 40.2x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 24.3% volatility.
Does DHR pay dividends?
Yes, Danaher Corporation offers a dividend yield of 0.70%. That is roughly $1.58 per share a year.
How volatile is DHR?
With 30-day annualized volatility of 24.3% and beta of 0.81, DHR is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for DHR?
The average analyst price target for Danaher Corporation (DHR) is $230.83 based on 23 analyst estimates, about 2.1% above the current price of $226.11. The published range runs from $195.00 to $310.00.
How much revenue does DHR generate?
Danaher Corporation reported $25.11B in trailing twelve-month revenue. Revenue growth is running at 5.5% year over year. Net margin sits at 15.9%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare DHR with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.